Endocannabinoid Levels Track with Pancreatitis Stage and Pain

In a case-control study of 231 participants, circulating anandamide (AEA) levels were significantly higher in pancreatitis patients compared to controls, with the highest levels in acute pancreatitis. Conversely, 2-AG levels were significantly lower in participants reporting abdominal pain in the past week, and pain intensity was inversely associated with both 2-AG and OEA concentrations.

Case-control study within the PROCEED cohort, measuring serum levels of two endocannabinoids (AEA, 2-AG) and two paracannabinoids (OEA, PEA) across five groups: no pancreatic disease (n=56), suspected/indeterminate chronic pancreatitis (n=22), acute pancreatitis (n=33), recurrent acute pancreatitis (n=57), and definite chronic pancreatitis (n=63).

This research maps how the body's own cannabinoid system responds to pancreatic disease and pain. The divergent patterns of AEA (elevated with disease) and 2-AG (depleted with pain) suggest the endocannabinoid system plays distinct roles in inflammation versus pain processing.

Understanding how endocannabinoid levels shift with disease and pain could eventually inform new treatment strategies, potentially including cannabinoid-based therapies for pancreatitis pain.

Cross-sectional design cannot determine whether endocannabinoid changes are a cause or consequence of disease. Relatively small group sizes. Serum levels may not reflect tissue-level endocannabinoid activity.